An observational study in Asthma, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Neutrophils and eosinophils can have different functions. Depending on their environment, they can be more or less active, with more or less inflammatory activity.
Biotherapies can reduce the number of inflammatory cells in the blood and bronchi. However, it is not known whether they have the ability to modify the functions of the remaining cells.
The aim of this study is to better understand the functioning of eosinophilic and neutrophil polynuclear drugs involved in the response to biotherapies in severe asthma. The hypothesis is that biotherapies modify the inflammatory functions of polynuclear cells, which would contribute to the effect of the drug on asthma.
Between 3 and 10% of adult asthmatics have a severe form of the disease. The pathophysiology of asthma is dominated by chronic bronchial inflammation of type "T2"" with eosinophil infiltration whose role in bronchial reshuffling, hyperresponsiveness and maintenance of inflammation has been well documented. They are specifically targeted by monoclonal antibodies to IL (inter leukin)-5, IL-5R and IL-4/13.
There is a population of severe asthmatics called "non-T2" characterized by Th17 inflammation, production of IL-6, IL-8, IL-11, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and IL-17 and preponderant bronchial recruitment of neutrophils, resulting in greater clinical severity and decreased sensitivity to corticosteroids. Neutrophils, not specifically targeted by the current therapies used, release reactive forms of oxygen, proteases, neutrophil extracellular traps (NETs) contributing to airway inflammation. The phenotypic heterogeneity, functional heterogeneity and plasticity of neutrophils has been studied in other pathologies but not specifically in asthma.
The response to biotherapies is not always optimal with a significant number of failures or escapes in clinical practice.
There are limited data on these eosinophilic and neutrophil leukocyte subpopulations in asthma, including phenotypic changes under biotherapies. Cellular functions have not been studied under treatment and clinical response is unknown. In addition, neutrophils and eosinophils are most often studied separately, while both cell types contribute to inflammation and can regulate each other.
This study hypothesize an impact of severe asthma biotherapies on the subpopulations and functionality of polynuclear drugs, contributing to the observed therapeutic effect.
This work could lead to a better understanding of the mechanisms of response to biotherapies.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's planned enrollment of 105 is below the median of 150 across 970 observational studies indexed under Asthma.
Browse Asthma studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Severe asthmatic patients followed in the Pneumology A department at Bichat Hospital.
Longitudinal group:
Cross-sectional group:
Exclusion Criteria:
25 patients anticipated. Patients with : * Uncontrolled asthma: ACT score \< 20 and/or at least one exacerbation in the last 6 months * Naïve biotherapy * Indication for initiation of biotherapy according to the referring pulmonologist (omalizumab, mepolizumab, benralizumab, dupilumab)
80 patients anticipated. * Patient on biotherapy (omalizumab, mepolizumab, benralizumab, dupilumab) for at least 6 months. * Controlled asthma (ACT \> 20 and no exacerbation for 6 months) or uncontrolled asthma (ACT \< 20 and/or at least 1 exacerbation for 6 months).
Measurement of the difference between the studied parameters of polynuclear cells measured at 6 months compared to those measured at the start of biotherapy.
The main objective will be to characterize the longitudinal evolution of markers measured at 6 months after initiation of biotherapy. These parameters will be studied on a fresh blood sample collected peripherally on a 7 mL EDTA (Ethylenediaminetetraacetic acid) tube and 5 mL dry tube on the day of inclusion at the time of day hospital or pulmonology consultation, before initiation and during a follow-up pneumology consultation/day hospital at 6 months post-initiation.
Time frame: 3 months for the longitudinal group and 9 months for the cross-sectional group
Measure the level of asthma control 6 months after the start of treatment, defined by the ACT score
Secondary objectives will be to measure an association of markers
Time frame: 3 months for the longitudinal group and 9 months for the cross-sectional group
Measure the number of exacerbations in the previous 6 months
Secondary objectives will be to measure an association of markers
Time frame: 3 months for the longitudinal group and 9 months for the cross-sectional group
Measure the type of biotherapy used
Secondary objectives will be to measure an association of markers
Time frame: 3 months for the longitudinal group and 9 months for the cross-sectional group
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris